The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury.
An L Moens; Hunter C Champion; Marc J Claeys; Barbara Tavazzi; Pawel M Kaminski; Michael S Wolin; Dirk J Borgonjon; Luc Van Nassauw; Azeb Haile; Muz Zviman; et al. (Profiled Authors: Hunter Champion; Menekhem Zviman; Nazareno Paolocci; David Kass; Kathleen Gabrielson; An Moens)
Johns Hopkins Medical Institutions, Division of Cardiology, Baltimore, MD 21205, USA.
BACKGROUND: The B vitamin folic acid (FA) is important to mitochondrial protein and nucleic acid synthesis, is an antioxidant, and enhances nitric oxide synthase activity. Here, we tested whether FA reduces myocardial ischemic dysfunction and postreperfusion injury. METHODS AND RESULTS: Wistar rats were pretreated with either FA (10 mg/d) or placebo for 1 week and then underwent in vivo transient left coronary artery occlusion for 30 minutes with or without 90 minutes of reperfusion (total n=131; subgroups used for various analyses). FA (4.5x10(-6) mol/L i.c.) pretreatment and global ischemia/reperfusion (30 minutes/30 minutes) also were performed in vitro (n=28). After 30 minutes of ischemia, global function declined more in controls than in FA-pretreated rats (Delta dP/dtmax, -878+/-586 versus -1956+/-351 mm Hg/s placebo; P=0.03), and regional thickening was better preserved (37.3+/-5.3% versus 5.1+/-0.6% placebo; P=0.004). Anterior wall perfusion fell similarly (-78.4+/-9.3% versus -71.2+/-13.8% placebo at 30 minutes), yet myocardial high-energy phosphates ATP and ADP reduced by ischemia in controls were better preserved by FA pretreatment (ATP: control, 2740+/-58 nmol/g; ischemia, 947+/-55 nmol/g; ischemia plus FA, 1332+/-101 nmol/g; P=0.02). Basal oxypurines (xanthine, hypoxanthine, and urate) rose with FA pretreatment but increased less during ischemia than in controls. Ischemic superoxide generation declined (3124+/-280 cpm/mg FA versus 5898+/-474 cpm/mg placebo; P=0.001). After reperfusion, FA-treated hearts had smaller infarcts (3.8+/-1.2% versus 60.3+/-4.1% placebo area at risk; P<0.002) and less contraction band necrosis, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling positivity, superoxide, and nitric oxide synthase uncoupling. Infarct size declined similarly with 1 mg/d FA. CONCLUSIONS: FA pretreatment blunts myocardial dysfunction during ischemia and ameliorates postreperfusion injury. This is coupled to preservation of high-energy phosphates, reducing subsequent reactive oxygen species generation, eNOS-uncoupling, and postreperfusion cell death.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Cristian Dumitrescu; Roberto Biondi; Yong Xia; Arturo J Cardounel; Lawrence J Druhan; Giuseppe Ambrosio; Jay L ZweierProceedings of the National Academy of Sciences of the United States of America 2007;104(38):15081-6.
Jae Hyung Kim; Lukasz J Bugaj; Young Jun Oh; Trinity J Bivalacqua; Sungwoo Ryoo; Kevin G Soucy; Lakshmi Santhanam; Alanah Webb; Andre Camara; Gautam Sikka; et al.Journal of applied physiology (Bethesda, Md. : 1985) 2009;107(4):1249-57.
S P Jones; W G Girod; A J Palazzo; D N Granger; M B Grisham; D Jourd'Heuil; P L Huang; D J LeferThe American journal of physiology 1999;276(5 Pt 2):H1567-73.
Appears in this Publication
Author of this Publication